Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Clinical trial NCT04468061 · RECRUITING

Trial details

NCT number: NCT04468061
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Triple Negative Breast Cancer PD-L1 Negative

Start date: 2020-07-20
Primary completion: 2027-04-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.